Featured Company: Vanda Pharmaceuticals, Inc. Rescues Abandoned Drugs

April 21, 2006 -- Vanda Pharma, which made its IPO debut on April 12 at $10 per share, was formed in 2003 with industry veterans who came from Novartis. The company seeks to in-license central nervous system drugs that have been abandoned by other companies after they failed to produce satisfactory results. Vanda intends to use its pharmacogenomics skills to identify more precisely defined patient subsets for whom the drugs will work effectively. We look at the company, its drug candidates and its finances...